33 results
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
9 May 24
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
4:17pm
, loss on debt extinguishment and restructuring charges related to our reduction in workforce. These non-GAAP financial measures are not prepared …
Impairment of out-license asset and remeasurement of CVR liability, net
Restructuring charges related to reduction in workforce(1)
Amortization
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
13 Mar 24
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
4:16pm
is expected to result in a reduction in workforce of 30% by the end of 2024, including 35 employees associated with the ophthalmology divestiture … of the reduction of workforce in 2024; and Coherus’ expectations that it will be able to realize value in the future from its pipeline.
Such forward-looking
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
6 Nov 23
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
4:31pm
of intangible assets, loss on debt extinguishment and restructuring charges related to our reduction in workforce. These non-GAAP financial measures … on debt extinguishment
Restructuring charges related to reduction in workforce(1)
Acquisition-related costs, including amortization of intangibles(2)
Non
8-K/A
EX-99.1
aaa5 mtziqw
6 Nov 23
Report of Independent Registered Public Accounting Firm
6:07am
8-K
EX-99.1
fdkovcse4w1nx6e
2 Aug 23
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
4:05pm
424B3
lwuyy 4qhc0gpy7o6di
26 Jul 23
Prospectus supplement
4:59pm
S-4/A
f6vp5os9dd
24 Jul 23
Registration of securities issued in business combination transactions (amended)
4:42pm
S-4
dehx1asxqk0dabr6514
7 Jul 23
Registration of securities issued in business combination transactions
5:03pm
425
kpc5i
16 Jun 23
Business combination disclosure
5:12pm
425
tb3flb3jry2xuqqr
16 Jun 23
Business combination disclosure
8:08am
425
wkb5zpt
16 Jun 23
Business combination disclosure
7:09am
8-K
EX-2.1
r7426l
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am
8-K
EX-99.1
5uz01re6s9
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am
8-K
EX-99.1
cug69988
8 May 23
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
4:16pm